Massachusetts Billion Dollar initiative, funding innovation in Life Sciences




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Massachusetts Billion Dollar initiative, funding innovation in Life Sciences
Released on: July 08, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Dr.
  • Summary
  • Transcript
  • Participants
Dr. Susan Windham-Bannister (keynote speaker at On Helix 2016 and Managing Partner of Biomedical Innovation Advisors) discusses the state-wide billion dollar initiative in Massachusetts, helping fund Life Sciences development over a 10 year period.
Dr. Susan Windham-Bannister (keynote speaker at On Helix 2016 and Managing Partner of Biomedical Innovation Advisors) discusses the state-wide billion dollar initiative in Massachusetts, helping fund Life Sciences development over a 10 year period.
Dr. Susan Windham-Bannister is a nationally and internationally recognized innovation expert. She was recognized by the Boston Globe as one of the “10 Most Influential Women in Biotech” in 2013. Dr. Windham-Bannister currently serves as Managing Partner of Biomedical Innovation Advisors LLC, which she founded with Dr. Harvey Lodish, co-founder of Genzyme and a member of the Whitehead Institute, MIT. She also serves as the President and CEO of Biomedical Growth Strategies, LLC. Both of these advisory firms leverage Dr. Windham-Bannister’s experience as the immediate past President and CEO of the Massachusetts Life Sciences Center (MLSC), a state-funded investment organization charged with administering the $1-billion Life Sciences fund that was proposed by Governor Deval Patrick in 2007 and signed into law in June 2008. The MLSC is the hub for all sectors of the Commonwealth’s life sciences community – biotechnology, pharmaceuticals, medical devices, medical diagnostics and bioinformatics. During her tenure as the founding executive of the MLSC, Dr. Windham-Bannister was responsible for the overall implementation of the Life Sciences Initiative, including formulating the investment strategy for the $1B fund, staffing and managing the organization, developing policies and procedures and building national and international partnerships. The MLSC’s portfolio of investments is promoting economic development, catalyzing innovation, strengthening Massachusetts’ global leadership position in the life sciences, and accelerating the commercialization of promising treatments, therapies and cures. Under Dr. Windham-Bannister’s leadership, the MLSC invested nearly $600 million of the fund, leveraged another $1.8 billion in matching investment capital, established Massachusetts as the global leader in life sciences, and made the life sciences the fastest job-producing sectors of the Massachusetts economy. In September 2013, the MLSC won the State Science and Technology Institute’s national competition for “Excellence in Technology-Based Economic Development. Before assuming her role at the MLSC, Dr. Windham-Bannister was co-founder and Managing Partner of Abt Bio-Pharma Solutions (ABS), a boutique consulting firm serving life sciences companies. In addition to serving as Managing Partner, Dr. Windham-Bannister led the firms Commercial Strategy Group, which formulated market access strategies for clients. In her 35-year consulting career, she has been instrumental in the successful launch of a number of well-known therapeutics, medical devices and novel biomarkers. She has supported a number of M&As and has extensive international experience. Her client base included early stage as well as Fortune 50 life sciences (Pfizer, Novartis, Roche, Merck), technology (IBM, GE) and financial services companies (CIGNA, Prudential, The Hartford, CitiGroup).